글로벌 연구동향
방사선종양학
- 2017년 01월호
[Radiat Oncol J.] Radiotherapy and immune checkpoint blockades: a snapshot in 2016서울대병원 / 구태률, 김인아*
- 출처
- Radiat Oncol J.
- 등재일
- 2016 Dec
- 저널이슈번호
- 34(4):250-259. doi: 10.3857/roj.2016.02033. Epub 2016 Dec 28.
- 내용
Abstract
Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.
Author informationKoo T1, Kim IA2.
1Department of Radiation Oncology, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
2Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
- 키워드
- Cytotoxic T-lymphocyte antigen-4; Immune checkpoint blockades; Programmed cell death 1 receptor; Radiotherapy
- 덧글달기
- 이전글 [Cancer Res Treat.] Post-mastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418)
- 다음글 [Oncotarget.] Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features.